Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia
Recursion Pharmaceuticals Call Volume Above Normal and Directionally Bullish
Recursion Pharmaceuticals (RXRX) Bold Acquisition Makes It a Leader in AI Drug Discovery
Express News | Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245, a Potential First-in-Class, Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Follow Nvidia's Lead in Investing in Small-Cap AI Stocks
